A comprehensive view of The Lancet. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Mitsubishi Tanabe Pharma Corp. publishes positive results from Phase 3 clinical study of ND0612 for Parkinson's disease treatment in The Lancet Neurology; NeuroDerm Ltd. conducted the study
Published: March 20, 2024 by ENP Newswire
Novavax Inc. - R21/Matrix-M™ Malaria Vaccine Phase 3 Trial Results Published in The Lancet
Published: February 02, 2024 by U.S. Markets (Alternative Disclosure) via PUBT
R21/Matrix-M™ Malaria Vaccine Phase 3 Trial Results Published in The Lancet
Published: February 02, 2024 by Novavax Inc.
AbbVie reports oral Ubrevy 100 mg significantly reduces the likelihood of developing moderate or severe headaches when administered during a migraine's prodrome phase; nearly 40 million in US are affected by migraines
Published: November 16, 2023 by AbbVie Inc.

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count